{
    "nct_id": "NCT03275974",
    "official_title": "Glutamine PET Imaging of Colorectal Cancer",
    "inclusion_criteria": "* ≥18 years of age;\n* Pathologically or cytologically confirmed diagnosis of metastatic (Stage IV) RAS wildtype CRC;\n* Eligible for anti-EGFR monoclonal antibody (mAb) therapy as standard-of-care (SOC), either as a single agent or in combination with approved SOC therapies or investigational agents as part of IRB-approved clinical trials;\n* Archived tissue from the CRC primary tumor in sufficient amounts to allow RNA-seq gene analysis; specimen from metastatic sites are not required but highly preferred;\n* Documented results from (or scheduled to undergo) CT or MRI of the chest, abdomen and pelvis as a standard-of-care procedure within 28 days of baseline investigational 11C-Gln PET/CT and 18F-FSPG PET/CT;\n* Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1;\n* At least one lesion >2 cm in diameter and thus will be measurable according to PET Response Criteria in Solid Tumors (PERCIST) v1.0 to avoid PET partial volume effects;\n* Ability to provide written informed consent in accordance with institutional policies.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Any other current or previous malignancy within the past 5 years\n* Previous EGFR-directed therapy\n* Body weight ≥ 400 pounds or body habitus or disability that will not permit the imaging protocol to be performed\n* Pregnant or lactating females",
    "miscellaneous_criteria": ""
}